Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenXSWX:BIIB 73 Cash-to-Debt is 0.15 as of Jun. 2026, which is 72% below its 10-year median of 0.54. GuruFocus rates XSWX:BIIB with a GF Score™ of 73/100 and a GF Value™ of CHF156.65. The stock has 10 warning signs investors should review. Among 984 Drug Manufacturers companies, Biogen ranks worse than 80.89% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biogen's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.15.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biogencouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Biogen's Cash-to-Debt or its related term are showing as below:
XSWX:BIIB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14 Med: 0.54 Max: 1
Current: 0.15
During the past 13 years, Biogen's highest Cash to Debt Ratio was 1.00. The lowest was 0.14. And the median was 0.54.
XSWX:BIIB's Cash-to-Debt is ranked worse than 80.89% of 984
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs XSWX:BIIB: 0.15
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Biogen Cash-to-Debt Related Terms
Biogen Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Biogen's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:BIIB vs OGN, AMRN, NSRX: Cash-to-Debt Comparison
For the Drug Manufacturers - General subindustry, Biogen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Biogen's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (XSWX:BIIB) has a Cash-to-Debt of 0.15 as of Jun. 2026. This is 72% below median its historical median of 0.54. Over the past decade, Biogen's Cash-to-Debt has ranged from 0.14 to 1.00. According to the industry distribution chart, Biogen ranks #796 out of 984 companies in the Drug Manufacturers industry, placing it in the top 80.9%.
Is Biogen's Cash-to-Debt too high?
Biogen's current Cash-to-Debt of 0.15 is 72% below median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.00. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Biogen's value of 0.15 is 84.4% below this industry median. Based on the distribution chart, Biogen ranks #796 out of 984 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biogen has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cash-to-Debt compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #796 out of 984 companies for Cash-to-Debt. This places Biogen in the lower half of its industry. The industry median Cash-to-Debt is 0.96. Biogen's value of 0.15 is 84.4% below this benchmark. Historically, Biogen's own Cash-to-Debt has ranged from 0.14 to 1.00 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 0.96, Biogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current Cash-to-Debt of 0.15 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current Cash-to-Debt is 0.15, which is 72% below median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Cash-to-Debt of 0.15. The stock's GF Value™ is CHF156.65, compared to a current price of CHF173.46 — trading 10.7% above its estimated fair value. The current Cash-to-Debt is 0.15, which is 72% below median its 10-year median of 0.54 and 84.4% below the Drug Manufacturers industry median of 0.96. Biogen's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Cash-to-Debt is 0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (XSWX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of CHF173.46 is trading 10.7% above its estimated GF Value™ of CHF156.65.
Key valuation signals for XSWX:BIIB:
Cash-to-Debt: 0.15 (72% below median its 10-year median of 0.54)
GF Value™: CHF156.65 vs. price of CHF173.46 (10.7% above fair value)
Industry Position: 84.4% below the Drug Manufacturers median (#796 of 984)
No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score
Get the complete analysis for XSWX:BIIB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIIB has been successfully added to your 
